National Cancer Institute and FDA Collaborate on HIV Treatment with Soluble Tat Peptide Analogs

Summary

The National Cancer Institute and the Food and Drug Administration are seeking a company to collaborate on the pre-clinical and clinical development of Soluble Tat Peptide Analogs, which have shown in vitro efficacy in inhibiting HIV transcription and replication, with FDA participation contingent on resolving conflict of interest issues.